Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Multiple Myeloma 2Melanoma 2Breast Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Sarcoma 1Resectable Pancreatic Cancer 1Resectable Esophageal Cancer 1Radiation Pneumonitis 1Pleural Mesothelial Neoplasm 1Neoplasms 1Neoplasm Metastasis 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Advanced Malignant Solid Tumor 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Specimen Handling 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Melanoma × Adjuvants, Immunologic × Clear all
NCT04594187 2026-02-17

MelPORT

M.D. Anderson Cancer Center

Phase 2 Recruiting
168 enrolled
Dermatologic

Melanoma

NCT00365937 2019-03-06

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 1/2 Terminated
19 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡